Research Article
Year 2019,
, 388 - 395, 30.06.2019
Abstract
89Zr,
uygun bozunum özellikleri, fiziksel yarı ömrü (t1/2 ~ 78 saat) nedeniyle artan
ilgi görmüştür ve bu nedenle de antikor temelli immüno-PET için uygun
görülmektedir. Relatif olarak salınan pozitronların düşük bozunum enerjisi
yüksek çözünürlüklü görüntü alınmasını sağlar. 89Zr-işaretli
radyofarmasötiklerinin insanda kullanımı özellikle 89Zr işaretli
antikorlar olarak immuno-PET de kullanımı günden güne artmaktadır.
Bu çalışmada, 89Zr
üretimi ile ilgili hesaplamalar yapılmış ve 89Y hedef sisteminin
kullanıldığı (p, n) reaksiyonu kullanılmıştır. Bunun için reaksiyon sonucu Bağ
Enerjisi, Eşik Enerjisi, Minimum Coulomb Bariyeri Enerjisi hesaplanmış, daha
sonra bu reaksiyonun tesir kesitleri Empire3.2/MALTA kodu kullanılarak
bulunmuştur. Işınlama hesaplamaları belirlendikten sonra proton bombardımanı
yapılmıştır. Bu ışınlama Ankara Sarayköy Nükleer Araştırma ve Eğitim
Merkezi'ndeki proton hızlandırıcısında gerçekleştirilmiştir. Kullanılan
siklotron IBA tipi Siklon-30'dur. Daha sonra ayırma kısmı Dowex reçine sistemi
ile yapılmıştır. Işınlanmış 89Zr, hedef sistemden ayrıldıktan sonra,
radyoaktif 89Zr saf olarak elde edilmiştir.
Keywords
References
- Adonai N., Nguyen K.N., Walsh J., Iyer M., Toyokuni T., Phelps M.E., McCarthy T., McCarthy D.W. and Gambhir S.S., Ex-vivo Cell Labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for Imaging Cell Trafficking in Mice with Positron Emission Tomography, Proc. Natl. Acad. Sci. U.S.A., 5 (2002), 99(5), 3030-3035.
- Aerts H.J.W.L., Dubois L., Perk L., Vermaelen P., van Dongen G.A.M.S., Wouters B.G. and Lambin P., Disparity Between in-vivo EGFR Expression and 89Zr Labeled Cetuximab Uptake Assessed with PET, J. Nucl. Med., 50 (2009), 123–131.
- Alfuraih A., Alzimami K., Ma A.K. and Alghamdi A, Optimization of 89Zr Production Using Monte Carlo Simulations, J. Radioanal. Nucl. Chem., 296 (2013), 1025–1029.
- Avila-Rodriguez M.A., Selwyn R.G., Converse A.K. and Nickles R.J., 86Y and 89Zr as PET Imaging Surrogates for 90Y: A Comparative Study, Proceedings of Ninth Mexican Symposium on Medical Physics, (2006) pp 45–47.
- Becker W., Emmrich F., Horneff G., Burmester G., Seiler F., Schwarz A., Kalden J. and Wolf F., Imaging Rheumatoid Arthritis Specifically with Technetium-99m CD4-specific (T-helper lymphocytes) Antibodies, Eur. J. Nucl. Med., 17, (1990), 156159.
- Borjesson P.K.E., Jauw Y.W.S., de Bree R., Roos J.C., Castelijns J., Leemans C.R., van Dongen G.AM.S. and Boellaard R., Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients, J. Nucl. Med., 50(11), (2009), 1828–1836.
- Borjesson P.K.E., Jauw Y.W.S., Boellaard R., de Bree R., Comans E.F.I., Roos J.C., Castelijns J.A., Vosjan M.J., Kummer J.A., Leemans C.R., Lammertma A.A. and van Dongen G.A., Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, 12 (2006), 2133-2140.
- Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., van Dongen G.A., Schröder C.P., Lub-de Hooge M.N. and de Vries E.G., Biodistribution of 89Zr-Trastuzumab and PET Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer, Clin. Pharmacol. Ther., 87 (2010), 586–592.
- Dijkers E.C.F., Kosterink J.G.W., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., de Jong J.R., de Vries E.G.E. and Lub-de Hooge M.N., Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, J. Nucl. Med., 50 (2009), 974–981.
- Disselhorst J.A., Brom M., Laverman P., Slump C.H., Boerman O.C., Oyen W.J.G., Gotthardt M. and Visser E.P., Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small Animal PET Scanner, J. Nucl. Med., 51 (2010), 610617.
- Firestein G.S., Evolving Concepts of Rheumatoid Arthritis, Nature 423 (6937), 35636115 (2003).
- Holland J.P., Sheh Y. and Lewis J.S., Standardized Methods for the Production of High Specific-Activity Zirconium-89, Nucl. Med. Biol., 36 (2009), 729–739.
- IAEA, IAEA-TRS-468: Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods, (2009), Vienna.
- Lampropoulou V., Calderon-Gomez E., Roch T., Neves P., Shen P., Stervbo U., Boudinot P., Anderton S.M. and Fillatreau S., Suppressive Functions of Activated B Cells in Autoimmune Diseases Reveal the Dual Roles of Toll-like Receptors in Immunity, Immunol. Rev., 233 (2010), 146161.
- Malviya G., Vries E.F.J.D., Dierckx R.A. and Signore, A., Radiopharmaceuticals for Imaging Chronic Lymphocytic Inflammation. Braz. Arch. Biol. Technol., 50 (2007), 1–13.
- Meijs W.E., Haisma H.J., Klok R.P., van Gog F.B., Kievit E., Pinedo H.M. and Herscheid J.D., Zirconium-Labeled Monoclonal Antibodies and Their Distribution in Tumor-Bearing Nude Mice, J. Nucl. Med., 38 (1997), 112–118.
- Nayak T.K. and Brechbiel M.W., Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges, Bioconjugate Chem., 20 (2009), 825–841.
- Perk L.R., Visser O.J., van Walsum M.S., Vosjan M.J.W.D., Visser G.W.M., Zijlstra J.M., Huijgens P.C. and van Dongen G.A.M.S., Preparation and Evaluation of (89)Zr-Zevalin for Monitoring of (90)Y-Zevalin Biodistribution with Positron Emission Tomography, Eur. J. Nucl. Med. Mol. Imaging, 33 (2006), 1337–1345.
- Toh M.L. and Miossec, P., The Role of T Cells in Rheumatoid Arthritis: New Subsets and New Targets, Curr. Opin. Rheumatol., 19 (2007), 284288.
- Van Dongen G.A.M.S., Visser G.W.M., Hooge M.N.L., De Vries E.G. and Perk L., Immuno-PET: a Navigator in Monoclonal Antibody Development and Applications, The Oncologist, 12 (2007), 1379–1389.
- Verel I., Visser G.W.M., Boellaard R., van Walsum M.S., Snow G.B. and van Dongen G.A.M.S., 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies, J. Nucl. Med., 44 (2003), 1271–1281.
- Verel I., Visser G.W.M. and van Dongen G.A.M.S., The Promise of Immuno-PET in Radioimmunotherapy, J. Nucl. Med., 46 (2005), 164s–171s.
- Walther M., Gebhardt P., Grosse-Gehling P., Wurbach L., Irmler I., Preusche S., Khalid M., Opfermann T., Kamradt T., Steinbach J. and Saluz H.P., Implementation of 89Zr Production and In-vivo Imaging of B-cells in Mice with 89Zr-Labeled Anti-B-Cell Antibodies by Small Animal PET/CT, Applied Radiation and Isotopes, 69 (2011), 852–857.
- Wu A.M., Antibodies and Antimatter: the Resurgence of Immuno-PET, J. Nucl. Med., 50 (2009)..
Year 2019,
, 388 - 395, 30.06.2019
Abstract
Nowadays 89Zr is outstanding PET radionuclide
with its physical half-life (t1/2 ~ 78 hours), useful decay specifications and
so that it is suitable for antibody-based immuno-PET. Relatively oscillated
positrons' low decay energies supply to take high-resolution. 89Zr-labeled
radiopharmaceuticals, especially as 89Zr-labeled antibodies applications are
getting increase day by day.
In this study, calculations about production of 89Zr were
done and used (p,n) reaction of 89Y target system. For this Q-value, Threshold
Energy, Minimum Coulomb Barrier Energy of the reaction were calculated then the
cross-sections of this reaction were found using Empire3.2/MALTA code. After
determining the irradiation calculations, the bombardment performed. The
irradiation was performed in Ankara Sarayköy Nuclear Research and Training
Center, proton accelerator. The cyclotron is IBA type Cyclone-30. Then
separation part was done with Dowex resine system. After separation 89Zr from
the irradiated target system, radioactive 89Zr was obtained purely.
References
- Adonai N., Nguyen K.N., Walsh J., Iyer M., Toyokuni T., Phelps M.E., McCarthy T., McCarthy D.W. and Gambhir S.S., Ex-vivo Cell Labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for Imaging Cell Trafficking in Mice with Positron Emission Tomography, Proc. Natl. Acad. Sci. U.S.A., 5 (2002), 99(5), 3030-3035.
- Aerts H.J.W.L., Dubois L., Perk L., Vermaelen P., van Dongen G.A.M.S., Wouters B.G. and Lambin P., Disparity Between in-vivo EGFR Expression and 89Zr Labeled Cetuximab Uptake Assessed with PET, J. Nucl. Med., 50 (2009), 123–131.
- Alfuraih A., Alzimami K., Ma A.K. and Alghamdi A, Optimization of 89Zr Production Using Monte Carlo Simulations, J. Radioanal. Nucl. Chem., 296 (2013), 1025–1029.
- Avila-Rodriguez M.A., Selwyn R.G., Converse A.K. and Nickles R.J., 86Y and 89Zr as PET Imaging Surrogates for 90Y: A Comparative Study, Proceedings of Ninth Mexican Symposium on Medical Physics, (2006) pp 45–47.
- Becker W., Emmrich F., Horneff G., Burmester G., Seiler F., Schwarz A., Kalden J. and Wolf F., Imaging Rheumatoid Arthritis Specifically with Technetium-99m CD4-specific (T-helper lymphocytes) Antibodies, Eur. J. Nucl. Med., 17, (1990), 156159.
- Borjesson P.K.E., Jauw Y.W.S., de Bree R., Roos J.C., Castelijns J., Leemans C.R., van Dongen G.AM.S. and Boellaard R., Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients, J. Nucl. Med., 50(11), (2009), 1828–1836.
- Borjesson P.K.E., Jauw Y.W.S., Boellaard R., de Bree R., Comans E.F.I., Roos J.C., Castelijns J.A., Vosjan M.J., Kummer J.A., Leemans C.R., Lammertma A.A. and van Dongen G.A., Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, 12 (2006), 2133-2140.
- Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., van Dongen G.A., Schröder C.P., Lub-de Hooge M.N. and de Vries E.G., Biodistribution of 89Zr-Trastuzumab and PET Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer, Clin. Pharmacol. Ther., 87 (2010), 586–592.
- Dijkers E.C.F., Kosterink J.G.W., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., de Jong J.R., de Vries E.G.E. and Lub-de Hooge M.N., Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, J. Nucl. Med., 50 (2009), 974–981.
- Disselhorst J.A., Brom M., Laverman P., Slump C.H., Boerman O.C., Oyen W.J.G., Gotthardt M. and Visser E.P., Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small Animal PET Scanner, J. Nucl. Med., 51 (2010), 610617.
- Firestein G.S., Evolving Concepts of Rheumatoid Arthritis, Nature 423 (6937), 35636115 (2003).
- Holland J.P., Sheh Y. and Lewis J.S., Standardized Methods for the Production of High Specific-Activity Zirconium-89, Nucl. Med. Biol., 36 (2009), 729–739.
- IAEA, IAEA-TRS-468: Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods, (2009), Vienna.
- Lampropoulou V., Calderon-Gomez E., Roch T., Neves P., Shen P., Stervbo U., Boudinot P., Anderton S.M. and Fillatreau S., Suppressive Functions of Activated B Cells in Autoimmune Diseases Reveal the Dual Roles of Toll-like Receptors in Immunity, Immunol. Rev., 233 (2010), 146161.
- Malviya G., Vries E.F.J.D., Dierckx R.A. and Signore, A., Radiopharmaceuticals for Imaging Chronic Lymphocytic Inflammation. Braz. Arch. Biol. Technol., 50 (2007), 1–13.
- Meijs W.E., Haisma H.J., Klok R.P., van Gog F.B., Kievit E., Pinedo H.M. and Herscheid J.D., Zirconium-Labeled Monoclonal Antibodies and Their Distribution in Tumor-Bearing Nude Mice, J. Nucl. Med., 38 (1997), 112–118.
- Nayak T.K. and Brechbiel M.W., Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges, Bioconjugate Chem., 20 (2009), 825–841.
- Perk L.R., Visser O.J., van Walsum M.S., Vosjan M.J.W.D., Visser G.W.M., Zijlstra J.M., Huijgens P.C. and van Dongen G.A.M.S., Preparation and Evaluation of (89)Zr-Zevalin for Monitoring of (90)Y-Zevalin Biodistribution with Positron Emission Tomography, Eur. J. Nucl. Med. Mol. Imaging, 33 (2006), 1337–1345.
- Toh M.L. and Miossec, P., The Role of T Cells in Rheumatoid Arthritis: New Subsets and New Targets, Curr. Opin. Rheumatol., 19 (2007), 284288.
- Van Dongen G.A.M.S., Visser G.W.M., Hooge M.N.L., De Vries E.G. and Perk L., Immuno-PET: a Navigator in Monoclonal Antibody Development and Applications, The Oncologist, 12 (2007), 1379–1389.
- Verel I., Visser G.W.M., Boellaard R., van Walsum M.S., Snow G.B. and van Dongen G.A.M.S., 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies, J. Nucl. Med., 44 (2003), 1271–1281.
- Verel I., Visser G.W.M. and van Dongen G.A.M.S., The Promise of Immuno-PET in Radioimmunotherapy, J. Nucl. Med., 46 (2005), 164s–171s.
- Walther M., Gebhardt P., Grosse-Gehling P., Wurbach L., Irmler I., Preusche S., Khalid M., Opfermann T., Kamradt T., Steinbach J. and Saluz H.P., Implementation of 89Zr Production and In-vivo Imaging of B-cells in Mice with 89Zr-Labeled Anti-B-Cell Antibodies by Small Animal PET/CT, Applied Radiation and Isotopes, 69 (2011), 852–857.
- Wu A.M., Antibodies and Antimatter: the Resurgence of Immuno-PET, J. Nucl. Med., 50 (2009)..
There are 24 citations in total.
Details
| Primary Language | English |
|---|---|
| Journal Section | Natural Sciences |
| Authors | |
| Publication Date | June 30, 2019 |
| Submission Date | July 27, 2018 |
| Acceptance Date | December 4, 2018 |
| Published in Issue | Year 2019 |